U-7524

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561076

CAS#: 645-88-5

Description: U-7524, also known as AOAA and Aminooxyacetic acid, is an inhibitor of 4-aminobutyrate aminotransferase (GABA-T). AOAA is also a general inhibitor of pyridoxal phosphate (PLP)-dependent enzymes (this includes GABA-T). It functions as an inhibitor by attacking the Schiff base linkage between PLP and the enzyme, forming oxime type complexes.


Price and Availability

Size
Price

Size
Price

Size
Price

U-7524.is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 561076
Name: U-7524
CAS#: 645-88-5
Chemical Formula: C2H5NO3
Exact Mass: 91.0269
Molecular Weight: 91.066
Elemental Analysis: C, 26.38; H, 5.53; N, 15.38; O, 52.71


Synonym: AOAA, Aminooxyacetic acid, 2-Aminooxyacetic acid, U 7524, U7524; U-7524

IUPAC/Chemical Name: 2-Aminooxyacetic acid

InChi Key: NQRKYASMKDDGHT-UHFFFAOYSA-N

InChi Code: InChI=1S/C2H5NO3/c3-6-1-2(4)5/h1,3H2,(H,4,5)

SMILES Code: O=C(O)CON


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Carmona E, Gomes C, Trolin G. Effect of aminooxyacetic acid (AOAA) on GABA levels in some parts of the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1980 May;312(1):51-5. PubMed PMID: 7393347.

2: Duvilanski BH, Seilicovich A, Díaz MC, Muñoz Maines V, Lasaga M, Debéljuk L. Effect of GABA-T inhibitors on prolactin secretion in vitro. Eur J Pharmacol. 1985 Sep 10;115(1):65-9. PubMed PMID: 4043235.

3: Neal MJ, Starr MS. Effect of inhibitors of -aminobutyrate aminotransferase on the accumulation of 3H- -aminobutyric acid by the retina. Br J Pharmacol. 1973 Mar;47(3):543-55. PubMed PMID: 4730831; PubMed Central PMCID: PMC1776273.

4: van der Laan JW, Weick G, van Bleek G. Effects of inhibitors of GABA-transaminase on hole-board exploration and on temperature. Relation with effects on quasi-morphine abstinence behaviour induced by sodium dipropylacetate. Biochem Pharmacol. 1985 Nov 1;34(21):3789-94. PubMed PMID: 3933514.

5: Löscher W, Hörstermann D. Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma. Naunyn Schmiedebergs Arch Pharmacol. 1994 Mar;349(3):270-8. PubMed PMID: 8208305.

6: Abe M, Matsuda M. Effect of antivitamin B6 on regional GABA metabolism in mouse brain and its relation to convulsions. J Nutr Sci Vitaminol (Tokyo). 1979;25(6):459-68. PubMed PMID: 541751.

7: Löscher W. A comparative study of the pharmacology of inhibitors of GABA-metabolism. Naunyn Schmiedebergs Arch Pharmacol. 1980;315(2):119-28. PubMed PMID: 6782493.

8: Löscher W, Hönack D, Gramer M. Use of inhibitors of gamma-aminobutyric acid (GABA) transaminase for the estimation of GABA turnover in various brain regions of rats: a reevaluation of aminooxyacetic acid. J Neurochem. 1989 Dec;53(6):1737-50. PubMed PMID: 2809589.

9: Sonnewald U, Kortner TM, Qu H, Olstad E, Suñol C, Bak LK, Schousboe A, Waagepetersen HS. Demonstration of extensive GABA synthesis in the small population of GAD positive neurons in cerebellar cultures by the use of pharmacological tools. Neurochem Int. 2006 May-Jun;48(6-7):572-8. Epub 2006 Mar 3. PubMed PMID: 16516347.

10: Oja SS, Kontro P. Effect of aminooxyacetic acid on the release of preloaded [3H]GABA and radioactive metabolites from slices of developing mouse brain. Neurochem Res. 1988 Oct;13(10):923-8. PubMed PMID: 3216949.

11: Sivam SP, Hudson PM, Tilson HA, Hong JS. GABA and dopamine interaction in the basal ganglia: dopaminergic supersensitivity following chronic elevation of brain gamma-aminobutyric acid levels. Brain Res. 1987 May 26;412(1):29-35. PubMed PMID: 3607459.

12: Tsukamoto K, Sved AF. Contrasting effects of the GABA transaminase inhibitors gamma-vinylGABA and aminooxyacetic acid on arterial pressure following injection into nucleus tractus solitarius. Neuropharmacology. 1993 Jun;32(6):575-9. PubMed PMID: 8336820.

13: Caron PC, Kremzner LT, Cote LJ. GABA and its relationship to putrescine metabolism in the rat brain and pancreas. Neurochem Int. 1987;10(2):219-29. PubMed PMID: 20501074.

14: Manev H, Pericić D. Hypothalamic GABA system and plasma corticosterone in ether stressed rats. Pharmacol Biochem Behav. 1983 Jun;18(6):847-50. PubMed PMID: 6889412.

15: Hedner T, Iversen K, Lundborg P. Central GABA mechanisms during postnatal development in the rat: neurochemical characteristics. J Neural Transm. 1984;59(2):105-18. PubMed PMID: 6726216.

16: van der Laan JW. Quasi-morphine withdrawal behaviour: indication for a specific involvement of the GABA-ergic nerve terminal compartment. Life Sci. 1983;33 Suppl 1:389-92. PubMed PMID: 6420629.

17: Löscher W, Hönack D, Gramer M. Effect of depth electrode implantation with or without subsequent kindling on GABA turnover in various rat brain regions. Epilepsy Res. 1999 Nov;37(2):95-108. PubMed PMID: 10510976.

18: Wilhelm EA, Gai BM, Souza AC, Bortolatto CF, Roehrs JA, Nogueira CW. Involvement of GABAergic and glutamatergic systems in the anticonvulsant activity of 3-alkynyl selenophene in 21 day-old rats. Mol Cell Biochem. 2012 Jun;365(1-2):175-80. doi: 10.1007/s11010-012-1257-3. Epub 2012 Feb 18. PubMed PMID: 22350757.

19: Zambotti F, Zonta N, Ferrario P, Zecca L, Mantegazza P. Effects of 2-chloroadenosine on hippocampal GABA content and turnover. J Neural Transm. 1986;65(3-4):167-75. PubMed PMID: 3711882.

20: Perry TL, Wright JM, Hansen S, Allan BM, Baird PA, MacLeod PM. Failure of aminooxyacetic acid therapy in Huntington disease. Neurology. 1980 Jul;30(7 Pt 1):772-5. PubMed PMID: 6446691.